CIK 0000914475
- Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330525145
- Phone
- +1 858-617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-05 | RASTETTER WILLIAM H Director | Sale 10b5-1 | −30,000 | $110.20 | $3.3M | 37,491 |
| 2025-05-05 | RASTETTER WILLIAM H Director | Option exercise · Non-Qualified Stock Option 10b5-1 | −30,000 | 0 | ||
| 2025-02-14 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −500 | $115.04 | $58K | 35,640 |
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Option exercise 10b5-1 | +1,509 | 20,340 | ||
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −796 | $116.77 | $93K | 19,544 |
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Option exercise 10b5-1 | +1,401 | 20,945 | ||
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Sale 10b5-1 | −755 | $116.80 | $88K | 20,190 |
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,509 | 3,020 | ||
| 2025-02-13 | Cooke Julie Chief Human Resources Officer | Option exercise · Restricted Stock Unit 10b5-1 | −1,401 | 4,203 | ||
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Option exercise 10b5-1 | +5,376 | 524,450 | ||
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Sale 10b5-1 | −2,832 | $116.69 | $330K | 521,618 |
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Option exercise 10b5-1 | +5,603 | 527,221 | ||
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Sale 10b5-1 | −3,012 | $116.68 | $351K | 524,209 |
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Option exercise · Restricted Stock Unit 10b5-1 | −5,376 | 10,754 | ||
| 2025-02-13 | GORMAN KEVIN CHARLES Director | Option exercise · Restricted Stock Unit 10b5-1 | −5,603 | 16,812 | ||
| 2025-02-13 | SHERWIN STEPHEN A Director | Sale 10b5-1 | −13,831 | $116.69 | $1.6M | 10,673 |
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise 10b5-1 | +2,113 | 35,366 | ||
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −1,114 | $116.90 | $130K | 34,252 |
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Option exercise 10b5-1 | +1,120 | 35,372 | ||
| 2025-02-13 | ROBERTS EIRY Chief Medical Officer | Sale 10b5-1 | −604 | $116.74 | $71K | 34,768 |
Page 20 of 49 · 963 trades